[en] BACKGROUND: Early identification of individuals at risk of dementia is mandatory to implement prevention strategies and design clinical trials that target early disease stages. Subjective cognitive decline (SCD) and neuropsychiatric symptoms (NPS) have been proposed as potential markers for early manifestation of Alzheimer's disease (AD). We aimed to investigate the frequency of NPS in SCD, in other at-risk groups, in healthy controls (CO), and in AD patients, and to test the association of NPS with AD biomarkers, with a particular focus on cognitively unimpaired participants with or without SCD-related worries.
METHODS: We analyzed data of n = 687 participants from the German DZNE Longitudinal Cognitive Impairment and Dementia (DELCODE) study, including the diagnostic groups SCD (n = 242), mild cognitive impairment (MCI, n = 115), AD (n = 77), CO (n = 209), and first-degree relatives of AD patients (REL, n = 44). The Neuropsychiatric Inventory Questionnaire (NPI-Q), Geriatric Depression Scale (GDS-15), and Geriatric Anxiety Inventory (GAI-SF) were used to assess NPS. We examined differences of NPS frequency between diagnostic groups. Logistic regression analyses were carried out to further investigate the relationship between NPS and cerebrospinal fluid (CSF) AD biomarkers, focusing on a subsample of cognitively unimpaired participants (SCD, REL, and CO), who were further differentiated based on reported worries.
RESULTS: The numbers of reported NPS, depression scores, and anxiety scores were significantly higher in subjects with SCD compared to CO. The quantity of reported NPS in subjects with SCD was lower compared to the MCI and AD group. In cognitively unimpaired subjects with worries, low Aß42 was associated with higher rates of reporting two or more NPS (OR 0.998, 95% CI 0.996-1.000, p < .05).
CONCLUSION: These findings give insight into the prevalence of NPS in different diagnostic groups, including SCD and healthy controls. NPS based on informant report seem to be associated with underlying AD pathology in cognitively unimpaired participants who worry about cognitive decline.
TRIAL REGISTRATION: German Clinical Trials Register DRKS00007966 . Registered 4 May 2015.
Disciplines :
Neurology
Author, co-author :
Sannemann, Lena ; Department of Psychiatry, Medical Faculty, University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany. lena.sannemann@uk-koeln.de
Schild, Ann-Katrin; Department of Psychiatry, Medical Faculty, University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany
Altenstein, Slawek; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117, Berlin, Germany
Bartels, Claudia; German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany ; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Von-Siebold-Str. 5, 37075, Goettingen, Germany
Brosseron, Frederic; German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127, Bonn, Germany ; Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
Buerger, Katharina; German Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-Lynen-Strasse 17, 81377, Munich, Germany ; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany
Cosma, Nicoleta Carmen; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Psychiatry and Psychotherapy, Hindenburgdamm 30, 12203, Berlin, Germany
Fliessbach, Klaus; German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127, Bonn, Germany ; Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
Freiesleben, Silka Dawn; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Psychiatry and Psychotherapy, Hindenburgdamm 30, 12203, Berlin, Germany
Glanz, Wenzel; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
HENEKA, Michael ; German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127, Bonn, Germany ; Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
Janowitz, Daniel; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany
Kilimann, Ingo; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany ; Department of Psychosomatic Medicine, Rostock University Medical Center, Gehlsheimer Str. 20, 18147, Rostock, Germany
Kobeleva, Xenia; German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127, Bonn, Germany ; Department of Neurology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
Laske, Christoph; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany ; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
Metzger, Coraline D; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany ; Department of Psychiatry and Psychotherapy, Otto-von-Guericke University, Magdeburg, Germany
Munk, Matthias H J; Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
Perneczky, Robert; German Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-Lynen-Strasse 17, 81377, Munich, Germany ; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany ; Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany ; Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, UK
Peters, Oliver; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Psychiatry and Psychotherapy, Hindenburgdamm 30, 12203, Berlin, Germany
Polcher, Alexandra; German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127, Bonn, Germany ; Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany ; Department of Neurology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
Priller, Josef; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117, Berlin, Germany
Rauchmann, Boris; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
Rösch, Christina; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Psychiatry and Psychotherapy, Hindenburgdamm 30, 12203, Berlin, Germany
Rudolph, Janna; German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
Schneider, Anja; German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127, Bonn, Germany ; Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
Spottke, Annika; German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127, Bonn, Germany ; Department of Neurology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
Spruth, Eike Jakob; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany ; Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117, Berlin, Germany
Teipel, Stefan; German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany ; Department of Psychosomatic Medicine, Rostock University Medical Center, Gehlsheimer Str. 20, 18147, Rostock, Germany
Vukovich, Ruth; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Von-Siebold-Str. 5, 37075, Goettingen, Germany
Wagner, Michael; German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127, Bonn, Germany ; Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
Wiltfang, Jens; German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany ; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Von-Siebold-Str. 5, 37075, Goettingen, Germany ; Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal
Wolfsgruber, Steffen; German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127, Bonn, Germany ; Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
Duezel, Emrah; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany ; Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany
Jessen, Frank; Department of Psychiatry, Medical Faculty, University of Cologne, Kerpener Strasse 62, 50924, Cologne, Germany ; German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127, Bonn, Germany ; Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Joseph-Stelzmann-Strasse 26, 50931, Köln, Germany
Deutsches Zentrum für Neurodegenerative Erkrankungen
Funding text :
The study was funded by the German Center for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen, DZNE), reference number BN012. Open Access funding enabled and organized by Projekt DEAL. Acknowledgements
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67. 10.1016/S1474-4422(13)70044-9. DOI: 10.1016/S1474-4422(13)70044-9
Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, et al. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement. 2011;7:532–9. 10.1016/J.JALZ.2011.05.2410. DOI: 10.1016/J.JALZ.2011.05.2410
Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement Geriatr Cogn Disord. 2008;25:115–26. 10.1159/000112509. DOI: 10.1159/000112509
Monastero R, Mangialasche F, Camarda C, Ercolani S, Camarda R. A systematic review of neuropsychiatric symptoms in mild cognitive impairment. J Alzheimers Dis. 2009;18:11–30. 10.3233/JAD-2009-1120. DOI: 10.3233/JAD-2009-1120
Liew TM. Neuropsychiatric symptoms in cognitively normal older persons, and the association with Alzheimer’s and non-Alzheimer’s dementia. Alzheimers Res Ther. 2020;12:35. 10.1186/s13195-020-00604-7. DOI: 10.1186/s13195-020-00604-7
Taragano FE, Allegri RF, Lyketsos C, Taragano FE, Allegri RF, Lyketsos C. Mild behavioral impairment: a prodromal stage of dementia. Dement Neuropsychol. 2008;2:256–60. 10.1590/S1980-57642009DN20400004. DOI: 10.1590/S1980-57642009DN20400004
Taragano FE, Allegri RF, Krupitzki H, Sarasola DR, Serrano CM, Loñ L, et al. Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J Clin Psychiatry. 2009;70:584–92. DOI: 10.4088/JCP.08m04181
Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K. Depressive symptoms, vascular disease, and mild cognitive impairment. Arch Gen Psychiatry. 2006;63:273. 10.1001/archpsyc.63.3.273. DOI: 10.1001/archpsyc.63.3.273
Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry. 2013;21:685–95. 10.1016/J.JAGP.2013.01.006. DOI: 10.1016/J.JAGP.2013.01.006
Geda YE, Roberts RO, Mielke MM, Knopman DS, Christianson TJH, Pankratz VS, et al. Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: a population-based study. Am J Psychiatry. 2014;171:572–81. 10.1176/appi.ajp.2014.13060821. DOI: 10.1176/appi.ajp.2014.13060821
Banks SJ, Raman R, He F, Salmon DP, Ferris S, Aisen P, et al. The Alzheimer’s disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline. Dement Geriatr Cogn Dis Extra. 2014;4:509–16. 10.1159/000357775. DOI: 10.1159/000357775
Masters MC, Morris JC, Roe CM. “Noncognitive” symptoms of early Alzheimer disease: a longitudinal analysis. Neurology. 2015;84:617–22. 10.1212/WNL.0000000000001238. DOI: 10.1212/WNL.0000000000001238
Ismail Z, Smith EE, Geda Y, Sultzer D, Brodaty H, Smith G, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12:195–202. 10.1016/j.jalz.2015.05.017. DOI: 10.1016/j.jalz.2015.05.017
Brodaty H, Heffernan M, Draper B, Reppermund S, Kochan NA, Slavin MJ, et al. Neuropsychiatric symptoms in older people with and without cognitive impairment. J Alzheimers Dis. 2012;31:411–20. 10.3233/JAD-2012-120169. DOI: 10.3233/JAD-2012-120169
Acosta I, Borges G, Aguirre-Hernandez R, Sosa AL, Prince M. Neuropsychiatric symptoms as risk factors of dementia in a Mexican population: a 10/66 Dementia Research Group study. Alzheimers Dement. 2018;14:271–9. 10.1016/j.jalz.2017.08.015. DOI: 10.1016/j.jalz.2017.08.015
Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10:844–52. 10.1016/j.jalz.2014.01.001. DOI: 10.1016/j.jalz.2014.01.001
van Harten AC, Visser PJ, Pijnenburg YAL, Teunissen CE, Blankenstein MA, Scheltens P, et al. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement. 2013;9:481–7. 10.1016/J.JALZ.2012.08.004. DOI: 10.1016/J.JALZ.2012.08.004
Reisberg B, Shulman MB, Torossian C, Leng L, Zhu W. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement. 2010;6:11–24. 10.1016/J.JALZ.2009.10.002. DOI: 10.1016/J.JALZ.2009.10.002
Jessen F, Wiese B, Bachmann C, Eifflaender-Gorfer S, Haller F, Kölsch H, et al. Prediction of dementia by subjective memory impairment effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry. 2010;67:414–22. 10.1001/archgenpsychiatry.2010.30. DOI: 10.1001/archgenpsychiatry.2010.30
Donovan NJ, Amariglio RE, Zoller AS, Rudel RK, Gomez-Isla T, Blacker D, et al. Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. Am J Geriatr Psychiatry. 2014;22:1642–51. 10.1016/j.jagp.2014.02.007. DOI: 10.1016/j.jagp.2014.02.007
Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, et al. Subjective cognitive decline and rates of incident Alzheimer’s disease and non–Alzheimer’s disease dementia. Alzheimers Dement. 2019;15:465–76. 10.1016/j.jalz.2018.10.003. DOI: 10.1016/j.jalz.2018.10.003
Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand. 2014;130. 10.1111/acps.12336.
Wolfsgruber S, Kleineidam L, Wagner M, Mösch E, Bickel H, Lϋhmann D, et al. Differential risk of incident Alzheimer’s disease dementia in stable versus unstable patterns of subjective cognitive decline. J Alzheimers Dis. 2016;54:1135–46. 10.3233/JAD-160407. DOI: 10.3233/JAD-160407
Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund L-O, Freund-Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8:619–27. 10.1016/S1474-4422(09)70139-5. DOI: 10.1016/S1474-4422(09)70139-5
Jessen F, Spottke A, Boecker H, Brosseron F, Buerger K, Catak C, et al. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE). Alzheimers Res Ther. 2018;10:15. 10.1186/s13195-017-0314-2. DOI: 10.1186/s13195-017-0314-2
Miebach L, Wolfsgruber S, Polcher A, Peters O, Menne F, Luther K, et al. Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. Alzheimers Res Ther. 2019;11:66. 10.1186/s13195-019-0515-y. DOI: 10.1186/s13195-019-0515-y
Snitz BE, Wang T, Cloonan YK, Jacobsen E, Chang C-CH, Hughes TF, et al. Risk of progression from subjective cognitive decline to mild cognitive impairment: the role of study setting. Alzheimers Dement. 2018;14:734–42. 10.1016/J.JALZ.2017.12.003. DOI: 10.1016/J.JALZ.2017.12.003
van Harten AC, Mielke MM, Swenson-Dravis DM, Hagen CE, Edwards KK, Roberts RO, et al. Subjective cognitive decline and risk of MCI: the Mayo Clinic Study of Aging. Neurology. 2018;91:e300–12. 10.1212/WNL.0000000000005863. DOI: 10.1212/WNL.0000000000005863
Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62. 10.1016/j.jalz.2018.02.018. DOI: 10.1016/j.jalz.2018.02.018
Wolfsgruber S, Kleineidam L, Guski J, Peters O, Buerger K, Ewers M, et al. Latent-factor structure of the DELCODE study neuropsychological test battery. Alzheimers Dement. 2017;13:P1136–7. 10.1016/j.jalz.2017.06.1655. DOI: 10.1016/j.jalz.2017.06.1655
Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the neuropsychiatric inventory. J Neuropsychiatry Clin Neurosci. 2000;12:233–9. 10.1176/jnp.12.2.233. DOI: 10.1176/jnp.12.2.233
Yesavage JA, Sheikh JI. 9/Geriatric depression scale (GDS) recent evidence and development of a shorter version. Clin Gerontol. 1986;5:165–73. DOI: 10.1300/J018v05n01_09
Brink TL, Yesavage JA, Lum O, Heersema PH, Adey M, Rose TL. Screening tests for geriatric depression. Clin Gerontol. 1982;1:37–43. 10.1300/J018v01n01_06. DOI: 10.1300/J018v01n01_06
Byrne GJ, Pachana NA. Development and validation of a short form of the Geriatric Anxiety Inventory – the GAI-SF. Int Psychogeriatrics. 2011;23:125–31. 10.1017/S1041610210001237. DOI: 10.1017/S1041610210001237
MacKin RS, Insel P, Aisen PS, Geda YE, Weiner MW. Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years. Int J Geriatr Psychiatry. 2012;27:355–63. 10.1002/gps.2713. DOI: 10.1002/gps.2713
Farias ST, Mungas D, Reed BR, Cahn-Weiner D, Jagust W, Baynes K, et al. The measurement of everyday cognition (ECog): scale development and psychometric properties. Neuropsychology. 2008;22:531–44. 10.1037/0894-4105.22.4.531. DOI: 10.1037/0894-4105.22.4.531
Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF A β 42/A β 40 and A β 42/A β 38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol. 2016;3:154–65. 10.1002/acn3.274. DOI: 10.1002/acn3.274
Comijs HC, Deeg DJH, Dik MG, Twisk JWR, Jonker C. Memory complaints; the association with psycho-affective and health problems and the role of personality characteristics: a 6-year follow-up study. J Affect Disord. 2002;72:157–65. 10.1016/S0165-0327(01)00453-0. DOI: 10.1016/S0165-0327(01)00453-0
Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19:271–8. 10.1016/S1474-4422(19)30368-0. DOI: 10.1016/S1474-4422(19)30368-0
Stella F, Forlenza OV, Laks J, de Andrade LP, de Castilho CJ, Govone JS, et al. Caregiver report versus clinician impression: disagreements in rating neuropsychiatric symptoms in Alzheimer’s disease patients. Int J Geriatr Psychiatry. 2015;30:1230–7. 10.1002/gps.4278. DOI: 10.1002/gps.4278
Tavares TP, Mitchell DGV, Coleman KK, Coleman BL, Shoesmith CL, Butler CR, et al. Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2020;91:jnnp-2020-322987. 10.1136/jnnp-2020-322987. DOI: 10.1136/jnnp-2020-322987
Escudero JMS, Beltrán J, Palacios Á, Chimbí CM, Matallana D, Reyes P, et al. Neuropsychiatric symptoms as predictors of clinical course in neurodegeneration. A longitudinal study. Front Aging Neurosci. 2019;10:176. 10.3389/fnagi.2019.00176. DOI: 10.3389/fnagi.2019.00176
Mendez MF, Perryman KM. Neuropsychiatric features of frontotemporal dementia: evaluation of consensus criteria and review. J Neuropsychiatry Clin Neurosci. 2002;14:424–9. 10.1176/jnp.14.4.424. DOI: 10.1176/jnp.14.4.424
Jessen F, Rodriguez Née Then FS. Not all, but specific types of cognitive complaints predict decline to MCI. Neurology. 2018;91:153–4. 10.1212/WNL.0000000000005872. DOI: 10.1212/WNL.0000000000005872
Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, et al. The Mild Behavioral Impairment Checklist (MBI-C): a rating scale for neuropsychiatric symptoms in pre-dementia populations. J Alzheimers Dis. 2017;56:929–38. 10.3233/JAD-160979. DOI: 10.3233/JAD-160979
